Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Electronic CTD Guidance Forces Applicants To Be More Scientific, CDER Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER’s guidance for electronic common technical documents eliminates the need for paper submissions for virtually every type of drug application. The eCTD forces companies to be more scientific and analyze what they are submitting to FDA, CDER’s Wilson says.

You may also be interested in...



FDA E-Labeling Guidance Sets Fall Goal For "Structured Product Labeling" Implementation

The final guidance provides three resources companies can access for assistance with SPL. FDA expects label changes for approved drugs will be submitted electronically using SPL by fall; the agency has not yet established a timeframe for unapproved drug labels.

FDA Planning Guidance On Analysis Datasets For Electronic Data Submissions

Datasets are needed to support analysis, programs or scripts used in an electronic regulatory submission, CDER Division of Biometrics II Deputy Director Wilson tells DIA symposium on clinical data management. Agency may eventually require analysis datasets to supplement standardized electronic clinical data submissions.

India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs

Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.

Topics

UsernamePublicRestriction

Register

PS062069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel